The module for proctitis is intended to assess bowel complications associated with pelvic irradiation for cancers located in the pelvic region. It is likely that the instrument will be suitable for use with non-radiation induced proctitis also.
A list of 38 potentially relevant issues was derived from a literature review. A pilot series of 'in depth' interviews with this list was undertaken to assess coverage and relevance. Feedback from 10 patients and 7 health care providers resulted in a list of 21 items. Systematic comparison with questions in the EORTC item bank led to modification of some questions. An additional pre-test was then conducted with 28 patients and 5 health care professionals to confirm the suitability of questions within the module. The results of the testing of the module in Australia are available in an article published in the International Journal of Radiation Oncology, Biology and Physics, Volume 72, No. 2, pp 522-528.
The module has been translated into several European languages. It has been pilot tested in Norway, Germany, France and Italy. Results from the pilot testing in Europe have been published in Radiotherapy and Oncology (doi:10.1016/j.radonc.2010.04.001).
The module is now identified as EORTC QLQ PRT23 because two additional items have been identified for inclusion.
Recruitment for Phase IV of the study, which involved large scale field testing of the module has been completed in the following countries: Australia, Canada, France, Germany, Italy and Norway.
Additional countries and sites can also participate in piloting and testing the module in different languages. Please contact us if you are interested in using the module.
Please contact us if you are interested in using the module.
A/Prof Georgia Halkett, Curtin University, Perth, Western Australia. Email: email@example.com.
Dr Nigel Spry, Radiation Oncology Department, Sir Charles Gairdner hospital, Perth, WA6009, Australia; Tel.: +61 8 9346 4900,Fax: +61 8 9346 3402.E-mail: Nigel.firstname.lastname@example.org